NovaDel said that a pharmacokinetic study of its improved oral spray formulation of sumatriptan demonstrated positive results. Sumatriptan is the active ingredient in GlaxoSmithKline’s leading migraine remedy, Imitrex.
Results from this pilot study demonstrate that sumatriptan oral spray achieves a statistically significant faster rate of absorption than Imitrex tablets. The rate of drug absorption is believed to be the most important predictor of the degree and speed of migraine relief.
“Migraine sufferers want rapid, effective and predictable relief and many experience nausea and vomiting during attacks making tablets difficult to take. We therefore believe our sumatriptan oral spray could provide migraine sufferers with a new, improved therapeutic alternative,” commented Jan Egberts, president and CEO of NovaDel.
Based on these positive findings NovaDel plans to complete the pivotal pharmacokinetic program in 2007 to support a new drug application.